Original Research

Published on 21 Feb 2024

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

in Respiratory Pharmacology

Aleksandr S. Chernov
Maksim V. Rodionov
Vitaly A. Kazakov
Karina A. Ivanova
Fedor A. Meshcheryakov
Anna A. Kudriaeva
Alexander G. Gabibov
Georgii B. Telegin
Alexey A. Belogurov

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351655

1,059 views

Original Research

Published on 13 Feb 2024

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

in Respiratory Pharmacology

Xuanyu Wu
Xiang Xiao
Hanyu Fang
Cuifang He
Hanyue Wang
Miao Wang
Peishu Lan
Fei Wang
Quanyu Du
Han Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1348708

1,708 views

Original Research

Published on 07 Feb 2024

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

in Respiratory Pharmacology

Kuang-Ming Liao
Chung-Yu Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1309712

1,044 views

Original Research

Published on 10 Jan 2024

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study

in Respiratory Pharmacology

Hélène Salvator
Elodie Lamy
Camille Roquencourt
Emmanuelle Bardin
Philippe Devillier
Stanislas Grassin-Delyle

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1339835

631 views

Review

Published on 08 Jan 2024

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

in Respiratory Pharmacology

Diya Garg
Loretta G. Que
Jennifer L. Ingram

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1315540

1,773 views

Case Report

Published on 08 Jan 2024

Case report: Fibrotic interstitial lung disease as the initial manifestation of hereditary pulmonary alveolar proteinosis caused by CSF2RB mutation

in Respiratory Pharmacology

Qiuhong Li
Huikang Xie
Manhui Li
Kebin Cheng

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1252193

857 views

Original Research

Published on 12 Dec 2023

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis

in Respiratory Pharmacology

Jin-Young Huh
Jae Ha Lee
Jin Woo Song

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1301923

2,076 views
2 citations

Review

Published on 11 Dec 2023

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis

in Respiratory Pharmacology

Liangtao Wen
Lixiang Xie
Fengying Gong
Shunan Zhang
Tieju Xi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1277284

1,442 views
2 citations

Editorial

Published on 06 Dec 2023

Editorial: Novel therapeutic strategies for the treatment of respiratory diseases

in Respiratory Pharmacology

Serena Di Vincenzo
Maria Ferraro
Maria Letizia Manca
Josè Esteban Peris
Elisabetta Pace

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1340116

555 views

Original Research

Published on 06 Dec 2023

Vitamin E stabilizes iron and mitochondrial metabolism in pulmonary fibrosis

in Respiratory Pharmacology

Jing Chang
Jiahui Wang
Beibei Luo
Weihao Li
Ziyue Xiong
Chaoqi Du
Xue Wang
Yuejiao Wang
Jingya Tian
Shuxin Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1240829

1,586 views

Review

Published on 06 Dec 2023

The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases

in Respiratory Pharmacology

Zhenglin He
Yihan Wang
Liang Han
Yue Hu
Xianling Cong

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1330518

1,886 views

Review

Published on 06 Dec 2023

Potential role of irisin in lung diseases and advances in research

in Respiratory Pharmacology

Hongna Dong
Xuejiao Lv
Peng Gao
Yuqiu Hao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1307651

1,881 views

Original Research

Published on 04 Dec 2023

Imperatorin ameliorates pulmonary fibrosis via GDF15 expression

in Respiratory Pharmacology

Cheng-Fang Tsai
Yen-Chang Chen
Ya-Zhen Li
Chen-Teng Wu
Pei-Chun Chang
Wei-Lan Yeh

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1292137

1,647 views
1 citation

Editorial

Published on 27 Nov 2023

Editorial: Perspectives in pharmacological therapy targeting cellular metabolic pathways in respiratory diseases

in Respiratory Pharmacology

Na Wang
Jie Liu
Peiran Yang
Dustin Fraidenburg
Haiyang Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1324586

690 views

Original Research

Published on 23 Nov 2023

Comparison of the effects of fentanyls and other μ opioid receptor agonists on the electrical activity of respiratory muscles in the rat

in Respiratory Pharmacology

Damiana Cavallo
Eamonn Kelly
Graeme Henderson
Ana Paula Abdala Sheikh

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1277248

1,684 views

Original Research

Published on 23 Nov 2023

A novel approach to pulmonary bronchial tree model construction and performance index study

in Respiratory Pharmacology

Yang Liu
Weiyan Qiu
Longyu Li
Rongchang Chen
Yan Kang
Shuangchen Ruan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1254804

844 views

Navigation group

Articles

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

Case report: Fibrotic interstitial lung disease as the initial manifestation of hereditary pulmonary alveolar proteinosis caused by CSF2RB mutation

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis

Editorial: Novel therapeutic strategies for the treatment of respiratory diseases

Vitamin E stabilizes iron and mitochondrial metabolism in pulmonary fibrosis

The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases

Potential role of irisin in lung diseases and advances in research

Imperatorin ameliorates pulmonary fibrosis via GDF15 expression

Editorial: Perspectives in pharmacological therapy targeting cellular metabolic pathways in respiratory diseases

Comparison of the effects of fentanyls and other μ opioid receptor agonists on the electrical activity of respiratory muscles in the rat

A novel approach to pulmonary bronchial tree model construction and performance index study